However, phase I–II clinical trials with recombinant TRAIL and agonistic antibodies for the TRAIL receptors, DR4 and DR5, have shown only isolated responses and limited overall effects on tumor progression [11, 12, 29, 30], indicating resistance of tumor cells to TRAIL-induced cell death. Here, TNFRSF10A is linked to neoplasm.